No specific drug-like molecular target identified

The designation "No specific drug-like molecular target identified" refers to a status in pharmacological research where a compound's therapeutic effect cannot be attributed to a specific protein, enzyme, or receptor. This situation frequently arises during phenotypic drug discovery, where substances are identified based on their ability to alter a disease phenotype in a cell or organism without prior knowledge of the molecular trigger (Source: Nature Reviews Drug Discovery, 2018). While some historical or legacy drugs operate through non-specific means—such as osmotic diuretics or general anesthetics that perturb lipid membranes—modern drug development prioritizes the identification of a discrete target to facilitate rational design and minimize toxicity (Source: StatPearls, 2023). The absence of a defined target poses significant hurdles for regulatory approval and the development of precision medicine strategies, as it limits the ability to monitor target engagement or select patients using biomarkers (Source: FDA, 2023). Consequently, this term serves as a placeholder in databases like ChEMBL or DrugBank to indicate that the molecular basis of a substance's bioactivity remains uncharacterized (Source: ChEMBL Database, 2024).

Other names

Unknown molecular targetUnidentified therapeutic targetNon-specific mechanism of action

The mechanism of action is either unknown, involves non-specific physical-chemical interactions, or has not yet been mapped to a specific biological macromolecule.